CDK9-IN-7

CDK9-IN-7

• CAS Number: 2369981-71-3
• UNSPSC Description: CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1].
• Target Antigen: Apoptosis; CDK
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/cdk9-in-7.html
• Purity: 98.05
• Solubility: DMSO : 62.5 mg/mL (ultrasonic)
• Smiles: O=C(N(C)C)C1=CC2=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N=C2N1C4CCCC4
• Molecular Weight: 547.71
• References & Citations: [1]Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported